Loading clinical trials...
Loading clinical trials...
A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in Patients Diagnosed as Knee Osteoarthritis
Conditions
Interventions
JointStem
Placebo Control
Locations
9
United States
TriWest Research Associates
El Cajon, California, United States
BioSolutions Clinical Research Center
La Mesa, California, United States
Neurovations Research
Napa, California, United States
Newport Therapeutics
Newport Beach, California, United States
Source Healthcare
Santa Monica, California, United States
Keimyung University Dongsan Hospital
Daegu, Korea, South Korea
Start Date
May 26, 2021
Primary Completion Date
December 30, 2026
Completion Date
December 31, 2026
Last Updated
July 24, 2025
NCT05986292
NCT06234631
NCT07364578
NCT06488144
NCT07058623
NCT06083480
Lead Sponsor
Nature Cell Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions